NextPharma, a European pharmaceutical CDMO, has completed the acquisition from Takeda of a state-of-the-art chewable tablets manufacturing site in Asker, Norway. The Asker site, which has approximately 170 employees and a high degree of production automation, has operated for more than 50 years, producing a broad portfolio of strengths and flavors of calcium/vitamin D3 chewable tablets.  The site will be NextPharma’s center of excellence for the development and manufacturing of chewable ta...